<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0103221785
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Vaprena
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TOLVAPTAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        3834.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jiangsu Hengrui Pharmaceuticals Co Ltd" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jiangsu Hengrui Pharmaceuticals Co Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C03XA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Vaprena, which contains the active substance tolvaptan, belongs to a group of medicines called vasopressin antagonists. Vasopressin is a hormone that helps prevent the loss of water from the body by reducing urine output. Antagonist means that it prevents vasopressin having its effect on water retention. This leads to a reduction in the amount of water in the body by increasing urine production and as a result it increases the level or concentration of sodium in your blood.</p><p>Vaprena is used to treat low serum sodium levels in adults. You have been prescribed this medicine because you have a lowered sodium level in your blood as a result of a disease called &ldquo;syndrome of inappropriate antidiuretic hormone secretion&rdquo; (SIADH) where the kidneys retain too much water. This disease causes an inappropriate production of the hormone vasopressin which has caused the sodium levels in your blood to get too low (hyponatremia). That can lead to difficulties in concentration and memory, or in keeping your balance.</p><p>Vasopressin hormone is involved in the formation of cysts in the kidneys of ADPKD patients. By blocking the effect of vasopressin, Vaprena slows the development of kidney cysts in patients with ADPKD, reduces symptoms of the disease and increases urine production.</p><p>Vaprena is a medicine used to treat a disease called &ldquo;autosomal dominant polycystic kidney disease&rdquo; (ADPKD). This disease causes growth of fluid-filled cysts in the kidneys, which puts pressure on surrounding tissues and reduces kidney function, possibly leading to kidney failure. Vaprena is used to treat ADPKD in adults with chronic kidney disease (CKD) stages 1 to 4 with evidence of rapidly progressing disease.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Vaprena </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to tolvaptan or any of the other ingredients of this medicine (listed in section 6) or if you are allergic to benzazepine or benzazepine derivatives (e.g. benazepril, conivaptan, fenoldopam mesylate or mirtazapine).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have been told that you have raised levels of liver enzymes in your blood which do not allow treatment with tolvaptan</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your kidneys do not work (no urine production).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a condition which increases the salt in your blood (&ldquo;hypernatremia&rdquo;).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a condition which is associated with a very low blood volume (e.g. severe dehydration or bleeding).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you do not realize when you are thirsty.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are pregnant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are breast-feeding.</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor or pharmacist before taking Vaprena:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you cannot drink enough water or if you are fluid restricted.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have difficulties in urination or have an enlarged prostate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from too high or too low blood sodium.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from liver disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you had an allergic reaction in the past to benzazepine, tolvaptan or other benzazepine derivatives (e.g. benazepril, conivaptan, fenoldopam mesylate or mirtazapine), or to any of the other ingredients of this medicine (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have been told you have high levels of a chemical called uric acid in your blood (which may have caused attacks of gout).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have advanced kidney disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have diabetes.</p><p><strong>This medicine may cause your liver to not work properly. Therefore, please inform your doctor immediately if you have signs that could indicate potential liver problems such as:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in the abdomen</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dark urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jaundice (yellowing of skin or eyes)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching of your skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flu-like syndrome (joint and muscle pain with fever)</p><p>&nbsp;</p><p><strong>During treatment with this medicine, your doctor will arrange monthly blood tests to check for changes in your liver function.</strong></p><p><u>Drinking enough water </u></p><p>Vaprena causes water loss because it increases your urine production. This water loss may result in side effects such as dry mouth and thirst or even more severe side effects like kidney problems (see section 4). It is therefore important that you have access to water and that you are able to drink sufficient amounts when you feel thirsty. Before bed-time you must drink 1 or 2 glasses of water even if you do</p><p>not feel thirsty and you must also drink water after you urinate at night. Special care must be taken if you have a disease that reduces appropriate fluid intake or if you are at an increased risk of water loss e.g. in case of vomiting or diarrhoea. Due to the increased urine production, it is also important that you always have access to a toilet.</p><p><strong>Children and adolescents </strong></p><p>Vaprena is not suitable for children and adolescents (under age 18).</p><p><strong>Other medicines and Vaprena </strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes all medicines obtained without a prescription.</p><p>The following medicines may increase the effect of this medicine:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amprenavir, atazanavir, darunavir/ritonavir and fosamprenavir (used to treat HIV/AIDS),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aprepitant (used to avoid nausea and vomiting in chemotherapy),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Crizotinib and imatinib (used to treat cancer),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ketoconazole, fluconazole or itraconazole (used to treat fungal infections),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Macrolide antibiotics like erythromycin or clarithromycin, quinolone antibiotics like ciprofloxacin,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Verapamil (used to treat heart diseases and high blood pressure),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diltiazem (used to treat high blood pressure and chest pain).</p><p>The following medicines may lower the effect of this medicine:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Phenytoin or carbamazepine (used to treat epilepsy),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rifampicin, rifabutin or rifapentine (used to treat tuberculosis),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St. John&rsquo;s Wort (a traditional herbal medicinal product for the relief of slightly low mood and mild anxiety).</p><p>This medicine may increase the effect of the following medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lovastatin, rosuvastatin (used to lower cholesterol in your blood)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sulfasalazine (used to treat inflammatory bowel disease or rheumatoid arthritis),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Digoxin (used to treat irregular heart beat and heart failure),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dabigatran (used to thin the blood),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Methotrexate (used to treat cancer, arthritis),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ciprofloxacin (an antibiotic),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Metformin (used to treat diabetes).</p><p>This medicine may lower the effect of the following medicines:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Desmopressin (used to increase blood clotting factors).</p><p>These medicines can affect or be affected by Vaprena:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diuretics (used to influence the production of urine). Taken with Vaprena these may increase the risk of side effects due to water loss or may cause kidney problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diuretics or other medicines for the treatment of high blood pressure. Taken with Vaprena these may increase the risk of low blood pressure when you stand up from sitting or lying down.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines which increase the level of sodium in your blood or which contain large amounts of salt (e.g. tablets that dissolve in water and indigestion remedies). These may increase the effect of Vaprena. There is a risk that this may lead to too much sodium in your blood.</p><p>It may still be alright for you to take these medicines and Vaprena together. Your doctor will be able to decide what is suitable for you.</p><p><strong>Vaprena with food and drink </strong></p><p>Avoid drinking grapefruit juice when taking Vaprena.</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><strong>Do not take </strong>this medicine if you are pregnant or breast-feeding.</p><p>Adequate contraceptive measures must be used during use of this medicine.</p><p><strong>Driving and using machines </strong></p><p>Vaprena is unlikely to adversely affect your ability to drive or to operate machinery. However, you may occasionally feel dizzy or weak or you may faint for a short period.</p><p><strong>Vaprena contains lactose</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>In case of using Vaprena for correction of hyponatremia:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment with Vaprena will be initiated in hospital.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For treatment of your low sodium (hyponatremia), your doctor will start with a dose of 15 mg and may then increase it to a maximum of 60 mg to achieve the desired level of serum sodium. To monitor the effects of Vaprena your doctor will do regular blood tests. To achieve the desired level of serum sodium your doctor can give in some instances a lower dose of 7.5 mg.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the tablet without chewing, with a glass of water.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take the tablets once a day preferably in the morning with or without food.</p><p><strong><em>In case of using Vaprena for autosomal dominant polycystic kidney disease ADPKD:</em></strong></p><p>Vaprena can be prescribed by doctors who are specialized in the treatment of ADPKD.</p><p><u>Dose</u></p><p>The daily amount of Vaprena is split into two doses, one bigger than the other. The higher dose should be taken in the morning when you wake up, at least 30 minutes before the morning meal. The lower dose is taken 8 hours later.</p><p>The dose combinations are:</p><p>45 mg + 15 mg</p><p>60 mg + 30 mg</p><p>90 mg + 30 mg</p><p>Your treatment will normally start with a dose of 45 mg in the morning and 15 mg 8 hours later. Your doctor may gradually increase your dose up to a maximum combination of 90 mg on waking and 30 mg after 8 hours. To find the best dose your doctor will regularly check how well you are tolerating a prescribed dose. You should always take the highest tolerable dose combination prescribed by your doctor.</p><p>If you take other medicines, which can increase the effects of Vaprena you may receive lower doses. In this case your doctor may prescribe you Vaprena tablets with 30 mg or 15 mg tolvaptan which have to be taken once a day in the morning.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Swallow the tablets without chewing, with a glass of water.</p><p>The morning dose is to be taken at least 30 minutes before the morning meal. The second daily dose can be taken with or without food.</p><p><strong>If you take more Vaprena than you should </strong></p><p>If you have taken more tablets than your prescribed dose, <strong>drink plenty of water and contact your doctor or your local hospital immediately</strong>. Remember to take the medicine pack with you so that it is clear what you have taken. If you take the higher dose very late in the day you may have to go to the toilet at night more frequently.</p><p><strong>If you forget to take Vaprena </strong></p><p>If you forget to take your medicine you have to take the dose as soon as you remember on the same day. If you do not take your tablet on one day, take your normal dose on the next day. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking Vaprena </strong></p><p>If you stop taking Vaprena this may lead to reoccurrence of your low sodium. If your doctor prescribed this medicine to you for ADPKD, your kidney cysts may grow as fast as they did before you started treatment with Vaprena.</p><p>Therefore, you should only stop taking Vaprena if you notice side effects requiring urgent medical attention (see section 4) or if your doctor tells you to.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>If you notice any of the following side effects, you may need urgent medical attention. Stop taking Vaprena and immediately contact a doctor or go to the nearest hospital if you: </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Find it difficult to urinate</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Find a swelling of the face, lips or tongue, itching, generalised rash, or severe wheezing or breathlessness (symptoms of an allergic reaction).</p><p><strong>Serious side effects: </strong></p><p><strong>Vaprena </strong><strong>may cause your liver not to work properly</strong><strong>.</strong></p><p>Consult your doctor if symptoms of nausea, vomiting, fever, tiredness, loss of appetite, pain in the abdomen, dark urine, jaundice (yellowing of skin or eyes), itching of your skin or joint and muscle pain with fever occur.</p><p><strong>Other side effects </strong></p><p><strong>Very common (may affect more than 1 in 10 people) </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thirst.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rapid rise in level of sodium.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dry mouth</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased need to urinate, to urinate at night, or to urinate more frequently</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatigue</p><p><strong>Common (may affect up to 1 in 10 people) </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excessive drinking of water.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dehydration</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High levels of sodium, potassium, creatinine, uric acid and blood sugar.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease in level of blood sugar.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Taste changes</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gout</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty sleeping</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fainting.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart pounding</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Belly pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Full or bloated or uncomfortable feeling in the stomach</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure when standing up.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heartburn</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal liver function</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dry skin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle spasms</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight loss</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight gain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patchy bleeding in the skin.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tiredness, general weakness.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; General feeling of being unwell.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood in urine.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Raised levels of liver enzymes in the blood.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Raised levels of creatinine in the blood.</p><p><strong>Uncommon (may affect up to 1 in 100 people) </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney problems.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase of bilirubin (a substance that can cause yellowing of skin or eyes) in the blood</p><p><strong>Not known (cannot be estimated from the available data) </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions (see above).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Generalized rash</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute liver failure (ALF).</p><p><strong>Reporting of side effects </strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p><p>By reporting side affects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the reach and sight of children.</p><p>Store below 30&ordm; C.</p><p>Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is tolvaptan.</p><p>Each Vaprena 15 mg tablet contains 15 mg tolvaptan.</p><p>Each Vaprena 30 mg tablet contains 30 mg tolvaptan.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: &nbsp;</p><p>Crospovidone NF, Povidone USP, Butylated Hydroxytoluene NF, Microcrystalline Cellulose NF, Lactose Monohydrate NF, Pregelatinized Starch NF, Croscarmellose Sodium NF, Colloidal Silicon Dioxide NF and Magnesium Stearate NF.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Vaprena 15 mg tablets: are non-scored, white, triangular, shallow-convex, debossed with “HR” and “15” on one side. 
Vaprena 30 mg: are non-scored, white, round, shallow-convex, debossed with “HR” and “30” on one side. 
Vaprena 15 mg and Vaprena 30 mg tablets are available as PVC/PVDC/Al/paper.
Blister pack: 10 tablets per blister for both 15 mg and 30 mg.
Unit Carton pack: 10, 20, 30 tablets per unit carton.
Not all pack sizes may be not marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturer:</strong> Jiangsu Hengrui Pharmaceuticals Co., Ltd.</p><p><strong>Marketing Authorization Holder:</strong></p><p>SPIMACO</p><p>Al-Qassim Pharmaceutical Plant</p><p>Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                November 2022.                                        
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ڨابرينا هو دواء يحتوي على المادة الفعالة تولڨابتان، وهو ينتمي إلى مجموعة من الأدوية تسمى مضادات فاسوبريسين. فاسوبريسين هو هرمون يساعد على منع فقدان الماء من الجسم عن طريق تقليل كمية البول. مضاد لهرمون فاسوبريسين يعني أنه يمنع تأثير فاسوبريسين على احتباس الماء. هذا يؤدي إلى انخفاض كمية الماء في الجسم عن طريق زيادة إنتاج البول ونتيجة لذلك يزيد من مستوى أو تركيز الصوديوم في الدم.</p><p dir="RTL">يستخدم ڨابرينا لعلاج انخفاض مستويات الصوديوم في الدم لدى البالغين. لقد تم وصف هذا الدواء لأن لديك مستوى منخفض من الصوديوم في الدم نتيجة لمرض يسمى &quot;متلازمة خلل في إفراز الهرمون المضاد لإدرار البول&quot; (SIADH) حيث تحتفظ الكليتان بالكثير من الماء. يتسبب هذا المرض في إنتاج غير مناسب لهرمون فاسوبريسين الذي تسبب في انخفاض مستويات الصوديوم في الدم (نقص صوديوم الدم). يمكن أن يؤدي ذلك إلى صعوبات في التركيز والذاكرة، أو في الحفاظ على توازنك.</p><p dir="RTL">يشارك هرمون فاسوبريسين في تكوين تكيسات في الكلى لدى المرضى المصابين بمرض الكلى الوراثي السائد متعدد التكيسات. عن طريق منع تأثير الفازوبريسين، يبطئ ڨابرينا من تطور تكيسات الكلى لدى المرضى المصابين بمرض الكلى الوراثي السائد متعدد التكيسات، ويقلل من أعراض المرض ويزيد من إفراز البول.</p><p dir="RTL">ڨابرينا هو دواء يستخدم لعلاج مرض يسمى &quot;مرض الكلى الوراثي السائد متعدد التكيسات&quot;. يتسبب هذا المرض في نمو أكياس مليئة بالسوائل في الكلى، مما يضغط على الأنسجة المحيطة ويقلل من وظائف الكلى، مما قد يؤدي إلى الفشل الكلوي. يستخدم ڨابرينا لعلاج مرض الكلى الوراثي السائد متعدد التكيسات لدى البالغين المصابين بأمراض الكلى المزمنة في المراحل 1 إلى 4 مع وجود دليل على تطور المرض لديهم بسرعة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تقم بتناول أقراص ڨابرينا في الحالات الآتية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية تجاه مادة تولڨابتان أو تجاه أي من المكونات الأخرى لهذا الدواء (والمذكورة في الفقرة رقم 6) أو إذا كانت لديك حساسية تجاه بنزازيبين أو أحد مشتقاته (مثل بينازبريل, كونيفابتان, فينولدوبام ميسيلات, أو ميرتازابين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تم إخبارك بأن لديك مستويات مرتفعة من إنزيمات الكبد في الدم والتي لا تسمح بالعلاج باستخدام تولڨابتان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لا تعمل لديك الكليتان (أي لا يتم إفراز البول).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حالة تزيد من مستوى الملح في الدم (&quot;فرط صوديوم الدم&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حالة مرتبطة بانخفاض في حجم الدم (على سبيل المثال جفاف شديد أو نزيف).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم تدرك أنك عطشان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملاً.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ ترضعين طفلك رضاعة طبيعية.</p><p dir="RTL"><strong>محاذير واحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك المعالج أو الصيدلي قبل تناول أقراص ڨابرينا في الحالات الآتية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت لا تستطيع شرب كمية كافية من الماء أو إذا كنت محظور من السوائل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك صعوبات في التبول أو تضخم البروستاتا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ارتفاع حاد أو انخفاض حاد في مستوى الصوديوم بالدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أمراض الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تعرضت مسبقاً لحساسية تجاه مادة تولڨابتان أو إذا كانت لديك حساسية تجاه بنزازيبين أو أحد مشتقاته (مثل بينازبريل, كونيفابتان, فينولدوبام ميسيلات, أو ميرتازابين) أو تجاه أي من المكونات الأخرى لهذا الدواء (والمذكورة في الفقرة رقم 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تم إخبارك بأن لديك بالدم مستويات مرتفعة من حمض البوليك (والتي قد تسبب نوبات النقرس).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مرض بالكلى في مرحلة متقدمة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بداء السكري.</p><p dir="RTL"><strong>قد يتسبب هذا الدواء في عدم عمل الكبد لديك بشكل صحيح. لذلك، يرجى إبلاغ طبيبك المعالج على الفور إذا كان لديك علامات يمكن أن تشير إلى مشاكل محتملة في الكبد مثل:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حُمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بول داكن اللون</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يرقان (اصفرار الجلد أو العينين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة في الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة شبيهة بالإنفلونزا (آلام المفاصل والعضلات مع الحمى)</p><p dir="RTL"><strong>أثناء العلاج بهذا الدواء، سيقوم طبيبك المعالج بترتيب فحوصات دم شهرية للتحقق من التغيرات في وظائف الكبد</strong><strong>.</strong></p><p dir="RTL"><u>شرب كمية كافية من الماء</u></p><p dir="RTL">ڨابرينا يسبب فقدان الماء لأنه يزيد من إنتاج البول. قد يؤدي فقدان الماء هذا إلى أعراض جانبية مثل جفاف الفم والعطش أو حتى أعراض جانبية أكثر حدة مثل مشاكل في الكلى (انظر الفقرة رقم 4). لذلك من المهم أن تحصل على الماء وأن تكون قادراً على شرب كميات كافية عندما تشعر بالعطش. قبل النوم يجب أن تشرب كوبًا أو كوبين من الماء حتى وإن كنت لا تشعر بالعطش وعليك أيضاً شرب الماء بعد التبول أثناء الليل. يجب توخي الحذر بشكل خاص إذا كنت تعاني من مرض يقلل من تناول السوائل بشكل مناسب أو إذا كنت في خطر متزايد لفقدان الماء على سبيل المثال في حالة القيء أو الإسهال. نظرًا لزيادة إنتاج البول، من المهم أيضًا أن يكون لديك دائمًا إمكانية الوصول إلى المرحاض.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">ڨابرينا غير مناسب للأطفال والمراهقين (الأقل في العمر من 18 سنة).</p><p dir="RTL"><strong>أدوية أخرى وڨابرينا</strong></p><p dir="RTL">أخبر طبيبك المعالج أو الصيدلي إذا كنت تتناول أو تناولت مؤخراً أو قد تتناول أي أدوية أخرى. وهذا يشمل جميع الأدوية التي تم الحصول عليها بدون وصفة طبية.</p><p dir="RTL">قد تزيد الأدوية التالية من تأثير هذا الدواء:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمبرينافير، أتازانافير، دارونافير/ ريتونافير وفوسامبرينافير (والتي تستخدم لعلاج فيروس نقص المناعة البشرية / الإيدز),</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أبريبيتانت (يستخدم لتجنب الغثيان والقيء في العلاج الكيميائي),</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كريزوتينيب وإيماتينيب (يستخدمان لعلاج السرطان),</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كيتوكونازول، فلوكونازول أو إيتراكونازول (والتي تستخدم لعلاج الالتهابات الفطرية),</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضادات الحيوية من مجموعة الماكروليدات مثل إريثروميسين أو كلاريثروميسين والمضادات الحيوية من مجموعة الكينولونات مثل سيبروفلوكساسين،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيراباميل (يستخدم لعلاج أمراض القلب وارتفاع ضغط الدم),</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديلتيازيم (يستخدم لعلاج ارتفاع ضغط الدم وألم الصدر),</p><p dir="RTL">قد تقلل الأدوية التالية من تأثير هذا الدواء:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينيتوين أو كاربامازيبين (لعلاج الصرع).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين أو ريفابوتين أو ريفابنتين (يستخدم لعلاج السل).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جون (منتج طبي عشبي تقليدي للتخفيف من الحالة المزاجية المنخفضة والقلق الخفيف).</p><p dir="RTL">قد يزيد هذا الدواء من تأثير الأدوية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لوفاستاتين، روسوفاستاتين (يستخدم لخفض نسبة الكوليسترول في الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سلفاسالازين (يستخدم لعلاج مرض التهاب الأمعاء أو التهاب المفاصل الروماتويدي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديجوكسين (يستخدم لعلاج عدم انتظام ضربات القلب وفشل القلب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دابيجاتران (يستخدم لتسييل الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثوتريكسات (يستخدم لعلاج السرطان والتهاب المفاصل).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيبروفلوكساسين (مضاد حيوي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميتفورمين (لعلاج مرض السكري).</p><p dir="RTL">قد يقلل هذا الدواء من تأثير الأدوية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديسموبريسين (يستخدم لزيادة عوامل تخثر الدم).</p><p dir="RTL">يمكن أن تؤثر هذه الأدوية أو تتأثر بـ ڨابرينا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مدرات البول (تستخدم للتأثير على إنتاج البول). قد يؤدي تناولها مع ڨابرينا إلى زيادة خطر الأعراض الجانبية بسبب فقدان الماء أو قد تسبب مشاكل في الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مدرات البول أو الأدوية الأخرى لعلاج ارتفاع ضغط الدم. قد يؤدي تناولها مع ڨابرينا إلى زيادة خطر انخفاض ضغط الدم عند الوقوف من الجلوس أو الاستلقاء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تزيد من مستوى الصوديوم في الدم أو التي تحتوي على كميات كبيرة من الملح (مثل الأقراص التي تذوب في الماء وعلاجات عسر الهضم). قد تزيد هذه من تأثير ڨابرينا. هناك خطر من أن هذا قد يؤدي ارتفاع مستوى الصوديوم لديك بالدم.</p><p dir="RTL">قد لا يزال من الجيد بالنسبة لك تناول هذه الأدوية وڨابرينا معاً. سيكون طبيبك قادراً على تحديد ما هو مناسب لك.</p><p dir="RTL"><strong>ڨابرينا مع الطعام والشراب</strong></p><p dir="RTL">تجنب شرب عصير الجريب فروت عند تناول ڨابرينا.</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنتِ حاملاً أو ترضعين طفلك طبيعياً, أو تعتقدين بأنكِ قد تكونين حاملاً أو تخططين لإنجاب طفل, اسألي طبيبك المعالج أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء.</p><p dir="RTL">يجب عليكِ عدم استخدام هذا الدواء إذا كنتِ حاملاً أو ترضعين طفلك طبيعياً.</p><p dir="RTL">يجب استخدام وسائل مناسبة لمنع الحمل أثناء استخدام هذا الدواء.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">من غير المحتمل أن يؤثر ڨابرينا سلباً على قدرتك على القيادة أو تشغيل الآلات. ومع ذلك، قد تشعر أحياناً بالدوار أو الضعف أو قد تشعر بالإغماء لفترة قصيرة.</p><p dir="RTL"><strong>ڨابرينا يحتوي على سكر اللاكتوز:</strong></p><p dir="RTL">إذا تم إبلاغك من قِبل طبيبك المعالج بعدم تحملك لبعض أنواع السكر, تواصل مع طبيبك المعالج قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قم دائماً بتناول هذا الدواء تماماً كما أخبرك طبيبك المعالج أو الصيدلي. استشِر طبيبك المعالج أو الصيدلي إذا لم تكن متأكداً.</p><p dir="RTL"><strong>في حالة استخدام </strong><strong>ڨابرينا</strong><strong> لتصحيح نقص مستوى الصوديوم بالدم:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يبدأ العلاج بأقراص ڨابرينا في المستشفى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج انخفاض مستوى الصوديوم (نقص الصوديوم بالدم), سيبدأ طبيبك المعالج معك بجرعة 15 ملجم, ثم قد يزيدها إلى 60 ملجم كحد أقصى لتحقيق المستوى المطلوب من الصوديوم في الدم. لمراقبة تأثير أقراص ڨابرينا, سيقوم طبيبك المعالج بإجراء فحوصات منتظمة للدم لديك. لتحقيق المستوى المطلوب من الصوديوم في الدم, يمكن لطبيبك المعالج أن يصف 7.5 ملجم كجرعة أقل في بعض الحالات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بابتلاع القرص كاملاً بدون مضغ, مع كوب من الماء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بتناول الأقراص مرة واحدة في اليوم ويفضل في الصباح مع أو بدون طعام.</p><p dir="RTL"><strong>في حالة استخدام </strong><strong>ڨابرينا</strong><strong> لعلاج مرض</strong><strong> الكلى ال</strong><strong>وراثي</strong><strong> السائد متعدد التكيسات</strong><strong>:</strong></p><p dir="RTL">يمكن وصف ڨابرينا من قبل الأطباء المتخصصين في علاج مرض الكلى الوراثي السائد متعدد التكيسات.</p><p dir="RTL"><u>الجرعة</u></p><p dir="RTL">تقسم الكمية اليومية من ڨابرينا إلى جرعتين، واحدة أكبر من الأخرى. يجب أن تؤخذ الجرعة الأعلى في الصباح عند الاستيقاظ، على الأقل 30 دقيقة قبل وجبة الصباح. يتم أخذ الجرعة الأقل بعد 8 ساعات.</p><p dir="RTL">تقسيم الجرعات كالتالي:</p><p dir="RTL">45 ملجم + 15 ملجم</p><p dir="RTL">60 ملجم + 30 ملجم</p><p dir="RTL">90 ملجم + 30 ملجم</p><p dir="RTL">سيبدأ علاجك عادة بجرعة 45 ملجم في الصباح و15 ملجم بعد 8 ساعات. قد يزيد طبيبك المعالج جرعتك تدريجيًا إلى جرعة قصوى قد تصل إلى 90 ملجم عند الاستيقاظ و30 ملجم بعد 8 ساعات. للعثور على أفضل جرعة، سيتحقق طبيبك المعالج بانتظام من مدى تحملك للجرعة الموصوفة. يجب عليك دائمًا تناول أعلى جرعة يمكن تحملها والتي وصفها لك طبيبك المعالج.</p><p dir="RTL">إذا كنت تتناول أدوية أخرى، والتي يمكن أن تزيد من تأثير ڨابرينا، فقد تتلقى جرعات أقل. في هذه الحالة، قد يصف لك طبيبك المعالج أقراص ڨابرينا التي تحتوي على 30 ملجم أو 15 ملجم من تولڨابتان<strong> </strong>والتي يجب تناولها مرة واحدة في اليوم في الصباح.</p><p dir="RTL"><u>طريقة تناول الدواء</u></p><p dir="RTL">قم بابتلاع الأقراص بدون مضغ مع كوب من الماء.</p><p dir="RTL">يجب أن تتناول جرعة الصباح قبل 30 دقيقة على الأقل من وجبة الصباح. يمكن تناول الجرعة اليومية الثانية مع الطعام أو بدونه.</p><p dir="RTL"><strong>في حالة تناول ڨابرينا أكثر مما يجب</strong></p><p dir="RTL">إذا كنت قد تناولت أقراصاً أكثر من جرعتك الموصوفة, فاشرب الكثير من الماء واتصل بطبيبك المعالج أو المستشفى المحلي على الفور. تذكر أن تأخذ عبوة الدواء معك لتوضيح ما قد تناولته. إذا كنت تتناول جرعة أعلى في وقت متأخر جدًا من اليوم، فقد تضطر إلى الذهاب إلى المرحاض في الليل بشكل متكرر.</p><p dir="RTL"><strong>في حالة نسيان تناول أقراص ڨابرينا</strong></p><p dir="RTL">إذا نسيت تناول الدواء, فيجب عليك تناول الجرعة حالما تتذكرها في نفس اليوم. إذا لم تتناول الجرعة الخاصة بك في يوم واحد, قم بتناول جرعتك المعتادة في اليوم التالي. لا تقم بمضاعفة الجرعة لتعويض الجرعة المنسية.</p><p dir="RTL"><strong>في حالة التوقف عن تناول أقراص ڨابرينا</strong></p><p dir="RTL">إذا توقفت عن تناول أقراص ڨابرينا قد يؤدي ذلك إلى انخفاض مستوى الصوديوم لديك بالدم مرة أخرى. إذا وصف لك طبيبك المعالج هذا الدواء لعلاج مرض الكلى الوراثي السائد متعدد التكيسات، فقد تنمو تكيسات الكلى بمعدل أسرع ما كانت عليه قبل بدء العلاج بأقراص ڨابرينا. لذلك, يجب عليك التوقف عن تناول أقراص ڨابرينا فقط إذا تعرضت لأعراض جانبية تتطلب العناية الطبية (انظر الفقرة رقم 4) أو إذا أخبرك طبيبك المعالج بالتوقف عن تناول هذا الدواء. إذا كانت لديك أي أسئلة إضافية بشأن هذا الدواء, اسأل طبيبك المعالج أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية, قد يسبب هذا الدواء أعراضاً جانبية, وإن لم تكن تحدث لكل من يتناول هذا الدواء.</p><p dir="RTL">إذا لاحظت أياً من الأعراض<strong> </strong>الجانبية التالية, فقد تحتاج إلى عناية طبية عاجلة. توقف عن تناول أقراص ڨابرينا واتصل بالطبيب المعالج على الفور أو اذهب إلى أقرب مستشفى في أي من الحالات الآتية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك صعوبة في التبول.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تورم في الوجه أو الشفتين أو اللسان أو تعاني من حكة أو طفح جلدي عام أو لديك صوت صفير شديد بالصدر أو ضيق في التنفس (وهي أعراض الحساسية).</p><p dir="RTL"><strong>أعراض جانبية خطيرة:</strong></p><p dir="RTL"><strong>قد يتسبب </strong><strong>ڨابرينا</strong><strong> في عدم عمل الكبد لديك بشكل صحيح</strong><strong>.</strong></p><p dir="RTL">استشِر طبيبك المعالج إذا ظهرت لديك أعراض غثيان، قيء، حمى، تعب، فقدان الشهية، ألم في البطن، بول داكن اللون أواليرقان (اصفرار الجلد أو العينين) أو حكة في الجلد أو آلام بالمفاصل والعضلات مع حمى.</p><p dir="RTL"><strong>أعراض جانبية أخرى</strong></p><p dir="RTL"><strong>شائعة جداً (قد تؤثر على أكثر من 1 من كل 10 أشخاص):</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالغثيان.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عطش.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع سريع في مستوى الصوديوم بالدم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الحاجة للتبول أو التبول في الليل أو التبول بشكل متكرر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إعياء</p><p dir="RTL"><strong>شائعة (قد تصيب ما يصل إلى 1 من كل 10 أشخاص):</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإفراط في شرب الماء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات الصوديوم والبوتاسيوم والكرياتينين وحمض البوليك والسكر بالدم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى السكر في الدم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة الشهية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في حاسة التذوق</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقرس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة النوم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خفقان القلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام البطن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالامتلاء أو الانتفاخ أو عدم راحة في المعدة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم عند الوقوف.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حرقة في المعدة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل في وظائف الكبد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الجلد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالمفاصل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات عضلية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالعضلات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف على شكل رقع في الجلد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب وضعف عام.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور عام بالإعياء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور دم في البول.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات إنزيمات الكبد في الدم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات الكرياتينين في الدم.</p><p dir="RTL"><strong>غير شائعة (قد تصيب ما يصل إلى 1 من كل 100 شخص):</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الكلى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة البيليروبين (مادة يمكن أن تسبب اصفرار الجلد أو العينين) في الدم.</p><p dir="RTL"><strong>غير معروفة (لا يمكن تقدير معدل حدوثها من خلال البيانات المتاحة):</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات تحسسية (انظر أعلاه).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي عام.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل الكبد الحاد.</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا كان لديك أي أعراض جانبية, فتحدث مع طبيبك المعالج أو الصيدلي. وهذا يشمل أي أعراض جانبية محتملة غير مدرجة في هذه النشرة.</p><p dir="RTL">من خلال الإبلاغ عن الأعراض<strong> </strong>الجانبية, يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ هذا الدواء بعيداً عن متناول ونظر الأطفال.</p><p dir="RTL">يحفظ هذا الدواء في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">لا يستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على الكرتون والشريط بعد كلمة EXP. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي: تولڨابتان.</p><p dir="RTL">ڨابرينا 15 ملجم: يحتوي كل قرص على 15 ملجم من مادة تولڨابتان.</p><p dir="RTL">ڨابرينا 30 ملجم: يحتوي كل قرص على 30 ملجم من مادة تولڨابتان.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مكونات أخرى وهي:</p><p dir="RTL">كروسبوفيدون NF, بوفيدون USP, بيوتيل هيدروكسي تولوين NF, سيليولوز دقيق التبلور NF, لاكتوز أحادي التميه NF, نشا قبل الهيلمة NF, كروسكار ميللوز الصوديوم NF, ثاني أكسيد سيليكون غروي NF, إستيارات مغنسيوم NF.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ڨابرينا 15 ملجم: هي أقراص غير قابلة للقسمة, بيضاء, مثلثة, ضحلة التحدب, منقوشة بـ &quot;HR&quot; و &quot;15&quot; على جانب واحد.</p><p dir="RTL">ڨابرينا 30 ملجم: هي أقراص غير قابلة للقسمة, بيضاء, مستديرة, ضحلة التحدب, منقوشة بـ &quot;HR&quot; و &quot;30&quot; على جانب واحد.</p><p dir="RTL">تتوافر أقراص ڨابرينا 15 ملجم وأقراص ڨابرينا 30 ملجم في شرائط من الألومنيوم PVC/PVDC/Al/paper.</p><p dir="RTL">شرائط العبوة: يحتوي كل شريط على 10 أقراص.</p><p dir="RTL">حجم العبوة: تحتوي كل عبوة على 10 أو 20 أو 30 قرصاً.</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إنتاج:</p><p dir="RTL"><strong>جیانقسو ھنجروي شركة الأدویة المحدودة, الصين.</strong></p><p dir="RTL"><strong>مالك الحقوق التسويقية:</strong></p><p dir="RTL"><strong>الدوائية</strong></p><p dir="RTL">مصنع الأدوية بالقصيم</p><p dir="RTL">الشركة السعودية للصناعات الدوائية والمستلزمات الطبية.</p><p dir="RTL">المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر 2022                                                            
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vaprena 15 mg tablets
Vaprena 30 mg tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vaprena 15 mg tablets
Each tablet contains 15 mg tolvaptan.
Vaprena 30 mg tablets
Each tablet contains 30 mg tolvaptan.
Excipient with known effect
Lactose monohydrate.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet.
Vaprena 15 mg tablets: are non-scored, white, triangular, shallow-convex, debossed with “HR” and “15” on one side. With complete, smooth and clear surface, the colour is uniform.
Vaprena 30 mg: are non-scored, white, round, shallow-convex, debossed with “HR” and “30” on one side. With complete, smooth and clear surface, the colour is uniform.  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vaprena is indicated in adults for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH).</p><p>Vaprena is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with chronic kidney disease (CKD) stage 1 to 4 at initiation of treatment with evidence of rapidly progressing disease (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Due to the need for a dose titration phase with close monitoring of serum sodium and volume status, treatment with Vaprena has to be initiated in hospital.</p><p>Tolvaptan treatment must be initiated and monitored under the supervision of physicians with expertise in managing ADPKD and a full understanding of the risks of tolvaptan therapy including hepatic toxicity and monitoring requirements (see section 4.4).</p><p><u>Posology</u></p><p>For correction of hyponatremia:</p><p>Tolvaptan has to be initiated at a dose of 15 mg once daily. The dose may be increased to a maximum of 60 mg once daily as tolerated to achieve the desired level of serum sodium.</p><p>For patients at risk of overly rapid correction of sodium e.g. patients with oncological conditions, very low baseline serum sodium, taking diuretics, or taking sodium supplementation a dose of 7.5 mg should be considered (see section 4.4).</p><p>During titration, patients must be monitored for serum sodium and volume status (see section 4.4). In case of inadequate improvement in serum sodium levels, other treatment options have to be considered, either in place of or in addition to tolvaptan. Use of tolvaptan in combination with other options may increase the risk of overly rapid correction of serum sodium (see sections 4.4 and 4.5). For patients with an appropriate increase in serum sodium, the underlying disease and serum sodium levels must be monitored at regular intervals to evaluate further need of tolvaptan treatment. In the setting of hyponatremia, the treatment duration is determined by the underlying disease and its treatment. Tolvaptan treatment is expected to last until the underlying disease is adequately treated or until such time that hyponatremia is no longer a clinical issue.</p><p>Vaprena must not be taken with grapefruit juice (see section 4.5).</p><p>For autosomal dominant polycystic kidney disease (ADPKD):</p><p>Vaprena is to be administered twice daily in split dose regimens of 45 mg + 15 mg, 60 mg + 30 mg or 90 mg + 30 mg. The morning dose is to be taken at least 30 minutes before the morning meal. The second daily dose can be taken with or without food. According to these split dose regimens the total daily doses are 60 mg, 90 mg, or 120 mg.</p><p><em>Dose titration:</em></p><p>The initial dose is 60 mg tolvaptan per day as a split-dose regimen of 45 mg + 15 mg (45 mg taken upon waking and prior the morning meal and 15 mg taken 8 hours later). The initial dose is to be titrated upward to a split-dose regimen of 90 mg tolvaptan (60 mg + 30 mg) per day and then to a target split dose regimen of 120 mg tolvaptan (90 mg + 30 mg) per day, if tolerated, with at least weekly intervals</p><p>between titrations. Dose titration has to be performed cautiously to ensure that high doses are not poorly tolerated through overly rapid up-titration. Patients may down-titrate to lower doses based on tolerability. Patients have to be maintained on the highest tolerable tolvaptan dose.</p><p>The aim of dose titration is to block activity of vasopressin at the renal V2 receptor as completely and constantly as possible, while maintaining acceptable fluid balance (see section 4.4).</p><p>Measurements of urine osmolality are recommended to monitor the adequacy of vasopressin inhibition.</p><p>Periodic monitoring of plasma osmolality or serum sodium (to calculate plasma osmolarity) and/or body weight should be considered to monitor the risk of dehydration secondary to the aquaretic effects of tolvaptan in case of patient&rsquo;s insufficient water intake.</p><p>The safety and efficacy of Vaprena in CKD stage 5 have not been explored and therefore tolvaptan treatment should be discontinued if renal insufficiency progresses to CKD stage 5 (see section 4.4).</p><p>Therapy must be interrupted if the ability to drink or the accessibility to water is limited (see section 4.4).</p><p>&nbsp;</p><p>Patients must be instructed to drink sufficient amounts of water or other aqueous fluids (see section 4.4).</p><p>In patients taking strong CYP3A inhibitors (see section 4.5), tolvaptan doses have to be reduced as follows:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Tolvaptan daily split-dose</p></td><td style="vertical-align:top"><p>Reduced dose (once daily)</p></td></tr><tr><td style="vertical-align:top"><p>90 mg + 30 mg</p></td><td style="vertical-align:top"><p>30 mg (further reduction to 15 mg if 30 mg are not well tolerated)</p></td></tr><tr><td style="vertical-align:top"><p>60 mg + 30 mg</p></td><td style="vertical-align:top"><p>30 mg (further reduction to 15 mg if 30 mg are not well tolerated)</p></td></tr><tr><td style="vertical-align:top"><p>45 mg + 15 mg</p></td><td style="vertical-align:top"><p>15 mg</p></td></tr></tbody></table><p><em>Dose adjustment for patients taking moderate CYP3A inhibitors</em></p><p>In patients taking moderate CYP3A inhibitors, tolvaptan doses have to be reduced as follows:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Tolvaptan daily split-dose</p></td><td style="vertical-align:top"><p>Reduced dose (once daily)</p></td></tr><tr><td style="vertical-align:top"><p>90 mg + 30 mg</p></td><td style="vertical-align:top"><p>45 mg + 15 mg</p></td></tr><tr><td style="vertical-align:top"><p>60 mg + 30 mg</p></td><td style="vertical-align:top"><p>30 mg + 15 mg</p></td></tr><tr><td style="vertical-align:top"><p>45 mg + 15 mg</p></td><td style="vertical-align:top"><p>15 mg + 15 mg</p></td></tr></tbody></table><p>Further reductions have to be considered if patients cannot tolerate the reduced tolvaptan doses.</p><p><u>Special populations </u></p><p><em>Elderly population</em></p><p>Increasing age has no effect on tolvaptan plasma concentrations. Limited data on the safety and effectiveness of tolvaptan in ADPKD patients aged over 55 are available (see section 5.1).</p><p>No dose adjustment is needed in elderly patients.</p><p><em>Renal impairment</em></p><p>Tolvaptan is contraindicated in anuric patients (see section 4.3).</p><p>Based on the data available, no dose adjustment is required in those with mild to moderate renal impairment.</p><p>No clinical trials in subjects with indices of glomerular filtration rate &lt; 10 mL/min or in patients undergoing dialysis have been conducted. The risk of hepatic damage in patients with severely reduced renal function (i.e. estimated glomerular filtration rate [eGFR] &lt; 20) may be increased; these patients should be carefully monitored for hepatic toxicity. Data for patients in CKD early stage 4 are more limited than for patients in stage 1, 2 or 3 (see section 5.1). Limited data are available for patients with CKD late stage 4 (eGFR &lt; 25 mL/min/1.73 m2). No data are available for patients with CKD stage 5. Tolvaptan treatment should be discontinued if renal insufficiency progresses to CKD stage 5 (see section 4.4).</p><p><em>Hepatic impairment</em></p><p>No dose adjustment is needed in patients with mild or moderate hepatic impairment (Child-Pugh classes A and B).</p><p>Vaprena is contraindicated in patients with elevated liver enzymes and/or signs or symptoms of liver injury prior to initiation of treatment that meet the requirements for permanent discontinuation of tolvaptan (see sections 4.3 and 4.4).</p><p><em>Paediatric population</em></p><p>The safety and efficacy of tolvaptan in children and adolescents under the age of 18 years have not yet been established. Vaprena is not recommended in the paediatric age group.</p><p><u>Method of administration</u></p><p>Oral use.</p><p>For correction of hyponatremia:</p><p>Administration preferably in the morning, without regard to meals. Tablets must be swallowed without chewing with a glass of water.</p><p>For autosomal dominant polycystic kidney disease (ADPKD):</p><p>The morning dose is to be taken at least 30 minutes before the morning meal. The second daily dose can be taken with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 or to benzazepine or benzazepine derivatives (see section 4.4)
• Anuria
• Volume depletion
• Hypovolemic hyponatremia
• Hypernatremia
• Patients who cannot perceive thirst
• Pregnancy (see section 4.6)
• Breast-feeding (see section 4.6)

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Urgent need to raise serum sodium acutely</u></p><p>Tolvaptan has not been studied in a setting of urgent need to raise serum sodium acutely. For such patients, alternative treatment has to be considered.</p><p><u>Access to water</u></p><p>Tolvaptan may cause adverse reactions related to water loss such as thirst, dry mouth and dehydration (see section 4.8). Therefore, patients must have access to water and be able to drink sufficient amounts of water. If fluid restricted patients are treated with tolvaptan, extra caution has to be exercised to ensure that patients do not become overly dehydrated.</p><p>Additionally, patients have to drink 1 to 2 glasses of fluid before bedtime regardless of perceived thirst and replenish fluids overnight with each episode of nocturia.</p><p><u>Dehydration</u></p><p>Volume status must be monitored in patients taking tolvaptan because treatment with tolvaptan may result in severe dehydration which constitutes a risk factor for renal dysfunction. Accurate monitoring of body weight is recommended. A progressive reduction in body weight could be an early sign of progressive dehydration. If dehydration becomes evident, take appropriate action, which may include the need to interrupt or reduce the dose of tolvaptan and increase fluid intake. Special care must be taken in patients having diseases that impair appropriate fluid intake or who are at an increased risk of water loss e.g. in case of vomiting or diarrhoea.</p><p><u>Urinary outflow obstruction</u></p><p>Urinary output must be secured. Patients with partial obstruction of urinary outflow, for example patients with prostatic hypertrophy or impairment of micturition, have an increased risk of developing acute retention.</p><p><u>Fluid and electrolyte balance</u></p><p>Fluid and electrolyte status has to be monitored in all patients and particularly in those with renal and hepatic impairment. Administration of tolvaptan may cause too rapid increases in serum sodium (&ge; 12 mmol/L per 24 hours, please see below); therefore, monitoring of serum sodium in all patients must start no later than 4-6 hours after treatment initiation. During the first 1-2 days and until the tolvaptan dose is stabilised serum sodium and volume status must be monitored at least every 6 hours.</p><p>Therefore, serum creatinine, electrolytes and symptoms of electrolyte imbalances (e.g. dizziness, fainting, palpitations, confusion, weakness, gait instability, hyper-reflexia, seizures, coma) have to be assessed prior to and after starting tolvaptan to monitor for dehydration.</p><p><u>Too rapid correction of serum sodium</u></p><p>Patients with very low baseline serum sodium concentrations may be at greater risk for too rapid correction of serum sodium.</p><p>Too rapid correction of hyponatremia (increase &ge; 12 mmol/L/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma or death. Therefore after initiation of treatment, patients have to be closely monitored for serum sodium and volume status (see above).</p><p>In order to minimize the risk of too rapid correction of hyponatremia the increase of serum sodium should be less than 10-12 mmol/L/24 hours and less than 18 mmol/L/48 hours. Therefore, more precautionary limits apply during the early treatment phase.</p><p>If sodium correction exceeds 6 mmol/L during the first 6 hours of administration or 8 mmol/L during the first 6-12 hours, respectively, the possibility that serum sodium correction may be overly rapid should be considered. These patients should be monitored more frequently regarding their serum sodium and administration of hypotonic fluid is recommended. In case serum sodium increases &ge; 12 mmol/L within 24 hours or &ge; 18 mmol/L within 48 hours, tolvaptan treatment is to be interrupted or discontinued followed by administration of hypotonic fluid.</p><p>In patients at higher risk of demyelination syndromes, for example those with hypoxia, alcoholism or malnutrition, the appropriate rate of sodium correction may be lower than that in patients without risk factors; these patients should be very carefully managed.</p><p>Patients who received other treatment for hyponatremia or medicinal products which increase serum sodium concentration (see section 4.5) prior to initiation of treatment with tolvaptan must be managed very cautiously. These patients may be at higher risk for developing rapid correction of serum sodium during the first 1-2 days of treatment due to potential additive effects.</p><p>Co-administration of tolvaptan with other treatments for hyponatremia, and medicinal products that increase serum sodium concentration, is not recommended during initial treatment or for other patients with very low baseline serum sodium concentrations (see section 4.5).</p><p><u>Diabetes mellitus</u></p><p>Diabetic patients with an elevated glucose concentration (e.g. in excess of 300 mg/dL) may present with pseudo-hyponatremia. This condition should be excluded prior and during treatment with tolvaptan.</p><p>Tolvaptan may cause hyperglycemia (see section 4.8). Therefore, diabetic patients treated with tolvaptan should be managed cautiously. In particular this applies to patients with inadequately controlled type II diabetes.</p><p><u>Uric acid increases</u></p><p>Decreased uric acid clearance by the kidney is a known effect of tolvaptan. In a double-blind, placebo controlled trial of patients with ADPKD, potentially clinically significant increased uric acid (greater than 10 mg/dL) was reported at a higher rate in tolvaptan-patients (6.2 %) compared to placebo-treated patients (1.7 %). Adverse reactions of gout were reported more frequently in tolvaptan-treated patients (28/961, 2.9 %) than in patients receiving placebo (7/483, 1.4 %). In addition, increased use of allopurinol and other medicinal products used to manage gout were observed in the double-blind, placebo-controlled trial. Effects on serum uric acid are attributable to the reversible renal hemodynamic changes that occur in response to tolvaptan effects on urine osmolality and may be clinically relevant.</p><p>However, events of increased uric acid and/or gout were not serious and did not cause discontinuation of therapy in the double-blind, placebo-controlled trial. Uric acid concentrations are to be evaluated prior to initiation of Vaprena therapy, and as indicated during treatment based on symptoms.</p><p>Effect of tolvaptan on glomerular filtration rate (GFR)</p><p>A reversible reduction in GFR has been observed in ADPKD trials at the initiation of tolvaptan treatment.</p><p><u>Idiosyncratic hepatic toxicity</u></p><p>Tolvaptan has been associated with idiosyncratic elevations of blood alanine and aspartate aminotransferases (ALT and AST) with infrequent cases of concomitant elevations in bilirubin-total (BT).</p><p>In post-marketing experience with tolvaptan in ADPKD, acute liver failure requiring liver transplantation has been reported (see section 4.8).</p><p>In a double-blind, placebo-controlled trial in patients with ADPKD, the period of onset of hepatocellular injury (by ALT elevations &gt; 3 &times; ULN) was within 3 to 14 months after initiating treatment and these increases were reversible, with ALT returning to &lt; 3 &times; ULN within 1 to 4 months. While these concomitant elevations were reversible with prompt discontinuation of tolvaptan, they represent a potential for significant liver injury. Similar changes with other medicinal products have been associated with the potential to cause irreversible and potentially life-threatening liver injury (see section 4.8).</p><p><strong>Prescribing physicians must comply fully with the safety measures required below.</strong></p><p>To mitigate the risk of significant and/or irreversible liver injury, blood testing for hepatic transaminases and bilirubin is required prior to initiation of Vaprena, continuing monthly for 18 months and at regular 3-monthly intervals thereafter. Concurrent monitoring for symptoms that may indicate liver injury (such as fatigue, anorexia, nausea, right upper abdominal discomfort, vomiting, fever, rash, pruritus, dark urine or jaundice) is recommended.</p><p>If a patient shows abnormal ALT, AST or BT levels prior to initiation of treatment which fulfil the criteria for permanent discontinuation (see below), the use of tolvaptan is contraindicated (see section 4.3). In case of abnormal baseline levels below the limits for permanent discontinuation treatment can only be initiated if the potential benefits of treatment outweigh the potential risks and liver function testing must continue at increased time frequency. The advice of a hepatologist is recommended.</p><p>During the first 18 months of treatment, Vaprena can only be supplied to patients whose physician has determined that liver function supports continued therapy.</p><p>At the onset of symptoms or signs consistent with hepatic injury or if clinically significant abnormal ALT or AST increases are detected during treatment, Vaprena administration must be immediately interrupted and repeat tests including ALT, AST, BT and alkaline phosphatase (AP) must be obtained as soon as possible (ideally within 48 hours to 72 hours). Testing must continue at increased time frequency until symptoms/signs/laboratory abnormalities stabilise or resolve, at which point Vaprena may be re-initiated.</p><p>Current clinical practice suggests that Vaprena therapy is to be interrupted upon confirmation of sustained or increasing transaminase levels and permanently discontinued if significant increases and/or clinical symptoms of hepatic injury persist.</p><p>Recommended guidelines for permanent discontinuation include:</p><p>&bull; ALT or AST &gt; 8-times ULN</p><p>&bull; ALT or AST &gt; 5-times ULN for more than 2 weeks</p><p>&bull; ALT or AST &gt; 3-times ULN and (BT &gt; 2-times ULN or International Normalised Ratio [INR] &gt; 1.5)</p><p>&bull; ALT or AST &gt; 3-times ULN with persistent symptoms of hepatic injury noted above.</p><p>If ALT and AST levels remain below 3-times the ULN, Vaprena therapy may be cautiously re-started, with frequent monitoring at the same or lower doses, as transaminase levels appear to stabilize during continued therapy in some patients.</p><p>In these clinical trials, clinically significant increases (greater than 3 &times; Upper Limit of Normal) in serum alanine aminotransferase (ALT), along with clinically significant increases (greater than 2 &times; Upper Limit of Normal) in serum total bilirubin were observed in 3 patients treated with tolvaptan. In addition, an increased incidence of significant elevations of ALT was observed in patients treated with tolvaptan [4.4 % (42/958)] compared to those receiving placebo [1.0 % (5/484)]. Elevation (&gt;3 &times; ULN) of serum aspartate aminotransferase (AST) was observed in 3.1 % (30/958) of patients on tolvaptan and 0.8 % (4/484) patients on placebo. Most of the liver enzyme abnormalities were observed during the first 18 months of treatment. The elevations gradually improved after discontinuation of tolvaptan. These findings may suggest that tolvaptan has the potential to cause irreversible and potentially fatal liver injury.</p><p>In a post-authorization safety study of tolvaptan in hyponatremia secondary to SIADH, several cases of hepatic disorders and elevated transaminases were observed (see section 4.8).</p><p>Liver function tests must be promptly performed in patients taking tolvaptan who report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice. If liver injury is suspected, tolvaptan must be promptly discontinued, appropriate treatment has to be instituted, and investigations have to be performed to determine the probable cause. Tolvaptan must not be re-initiated in patients unless the cause for the observed liver injury is definitively established to be unrelated to treatment with tolvaptan.</p><p><u>Anaphylaxis</u></p><p>In post-marketing experience, anaphylaxis (including anaphylactic shock and generalized rash) has been reported very rarely following administration of tolvaptan. This type of reaction occurred after the first administration of tolvaptan. Patients have to be carefully monitored during treatment. Patients with known hypersensitivity reactions to benzazepine or benzazepine derivatives (e.g. benazepril, conivaptan, fenoldopam mesylate or mirtazapine) may be at risk for hypersensitivity reaction to tolvaptan (see section 4.3 Contraindications).</p><p>If an anaphylactic reaction or other serious allergic reactions occur, administration of tolvaptan must be discontinued immediately and appropriate therapy initiated. Since hypersensitivity is a contraindication (see section 4.3) treatment must never be restarted after an anaphylactic reaction or other serious allergic reactions.</p><p><u>Lactose intolerance</u></p><p>Vaprena contains lactose as an excipient. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Co-administration with other treatments for hyponatremia and medicinal products that increase serum sodium concentration</u></p><p>There is no experience from controlled clinical trials with concomitant use of Vaprena and other treatments for hyponatremia such as hypertonic sodium chloride solution, oral sodium formulations, and medicinal products that increase serum sodium concentration. Medicinal products with high sodium content such as effervescent analgesic preparations and certain sodium containing treatments for dyspepsia may also increase serum sodium concentration. Concomitant use of Vaprena with other treatments for hyponatremia or other medicinal products that increase serum sodium concentration may result in a higher risk for developing rapid correction of serum sodium (see section 4.4) and is therefore not recommended during initial treatment or for other patients with very low baseline serum sodium concentrations where rapid correction may represent a risk for osmotic demyelination (see section 4.4).</p><p><u>CYP3A4 inhibitors</u></p><p>Concomitant use of medicinal products that are moderate CYP3A inhibitors (e.g. amprenavir, aprepitant, atazanavir, ciprofloxacin, crizotinib, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, imatinib, verapamil) or strong CYP3A inhibitors (e.g. itraconazole, ketoconazole, ritonavir, clarithromycin) increase tolvaptan exposure.</p><p>Co-administration of tolvaptan and ketoconazole resulted in a 440 % increase in area under time-concentration curve (AUC) and 248 % increase in maximum observed plasma concentration (Cmax) for tolvaptan.</p><p>Co-administration of tolvaptan and fluconazole, a moderate CYP3A inhibitor, produced a 200 % and 80 % increase in tolvaptan AUC and Cmax, respectively.</p><p>Co-administration of tolvaptan with grapefruit juice, a moderate to strong CYP3A inhibitor, produced a doubling of peak tolvaptan concentrations (Cmax).</p><p>Dose reduction of tolvaptan is recommended for patients while taking moderate or strong CYP3A inhibitors (see section 4.2). Patients taking moderate or strong CYP3A inhibitors must be managed cautiously, in particular if the inhibitors are taken more frequently than once a day.</p><p><u>CYP3A4 </u>inducers</p><p>Concomitant use of medicinal products that are potent CYP3A inducers (e.g. rifampicin) will decrease tolvaptan exposure and efficacy. Co-administration of tolvaptan with rifampicin reduces Cmax and AUC for tolvaptan by about 85 %. Therefore, concomitant administration of tolvaptan with potent CYP3A inducers (e.g. rifampicin, rifabutin, rifapentine, phenytoin, carbamazepine, and St. John&rsquo;s Wort) is to be avoided.</p><p><em>Co-administration with medicinal products that increase serum sodium concentration</em></p><p>There is no experience from controlled clinical trials with concomitant use of tolvaptan and hypertonic sodium chloride solution, oral sodium formulations, and medicinal products that increase serum sodium concentration. Medicinal products with high sodium content such as effervescent analgesic preparations and certain sodium containing treatments for dyspepsia may also increase serum sodium concentration. Concomitant use of tolvaptan with medicinal products that increase serum sodium concentration may result in a higher risk for developing hypernatraemia and is therefore not recommended.</p><p>Effect of tolvaptan on the pharmacokinetics of other products</p><p><u>CYP3A4 substrates</u></p><p>In healthy subjects, tolvaptan, a CYP3A4 substrate, had no effect on the plasma concentrations of some other CYP3A4 substrates (e.g. warfarin or amiodarone). Tolvaptan increased plasma levels of lovastatin by 1.3- to 1.5-fold. Even though this increase has no clinical relevance, it indicates tolvaptan can potentially increase exposure to CYP3A4 substrates.</p><p>Transporter substrates</p><p>P-glycoprotein substrates: In-vitro studies indicate that tolvaptan is a substrate and competitive inhibitor of P-glycoprotein (P-gp). Steady state digoxin concentrations were increased (1.3-fold in maximum observed plasma concentration [Cmax] and 1.2-fold in area under the plasma concentration-time curve over the dosing interval [AUC&tau;]) when co-administered with multiple once daily 60 mg doses of tolvaptan. Patients receiving digoxin or other narrow therapeutic P-gp substrates (e.g. dabigatran) must therefore be managed cautiously and evaluated for excessive effects when treated with tolvaptan.</p><p>OATP1B1/OAT3/BCRP and OCT1: In-vitro studies indicate that tolvaptan or its oxobutyric metabolite may have the potential to inhibit OATP1B1, OAT3, BCRP and OCT1 transporters. Co-administration of tolvaptan (90 mg) with rosuvastatin (5 mg), a BCRP substrate, increased rosuvastatin Cmax and AUCt of 54 % and 69 %, respectively. If BCRP substrates (e.g. sulfasalazine) are co-administered with tolvaptan, patients must be managed cautiously and evaluated for excessive effects of these medicinal products.</p><p>Administration of rosuvastatin (OATP1B1 substrate) or furosemide (OAT3 substrate) to healthy subjects with elevated oxobutyric acid metabolite (inhibitor of OATP1B1 and OAT3) plasma concentrations did not meaningfully alter the pharmacokinetics of rosuvastatin or furosemide. Statins commonly used in the tolvaptan phase 3 pivotal trial (e.g. rosuvastatin and pitavastatin) are OATP1B1 or OATP1B3 substrates, however no difference in adverse events profile was observed during the phase 3 pivotal trial for tolvaptan in ADPKD.</p><p>If OCT1 substrates (e.g. metformin) are co-administered with tolvaptan, patients must be managed cautiously and evaluated for excessive effects of these medicinal products.</p><p>Diuretics or non-diuretic anti-hypertensive medicinal product(s)</p><p>Standing blood pressure was not routinely measured in ADPKD trials. Therefore, a risk of orthostatic/postural hypotension due to a pharmacodynamic interaction with tolvaptan cannot be excluded</p><p><u>Diuretics</u></p><p>While there does not appear to be a synergistic or additive effect of concomitant use of tolvaptan with loop and thiazide diuretics, each class of agent has the potential to lead to severe dehydration, which constitutes a risk factor for renal dysfunction. If dehydration or renal dysfunction becomes evident, take appropriate action which may include the need to interrupt or reduce doses of tolvaptan and/or diuretics, increase fluid intake, evaluate and address other potential causes of renal dysfunction or dehydration.</p><p><u>Digoxin</u></p><p>Steady state digoxin concentrations have been increased (1.3-fold increase in maximum observed plasma concentration [C<sub>max</sub>] and 1.2-fold increase in area under the plasma concentration-time curve over the dosing interval [AUC ]) when co administered with multiple once daily 60 mg doses of tolvaptan. Patients receiving digoxin should therefore be evaluated for excessive digoxin effects when treated with tolvaptan.</p><p><u>Co-administration with vasopressin analogues</u></p><p>In addition to its renal aquaretic effect, tolvaptan is capable of blocking vascular vasopressin V2-receptors involved in the release of coagulation factors (e.g., von Willebrand factor) from endothelial cells. Therefore, the effect of vasopressin analogues such as desmopressin may be attenuated in patients using such analogues to prevent or control bleeding when co-administered with tolvaptan. It is not recommended to administer Vaprena with vasopressin analogues.</p><p><em>Smoking and alcohol</em></p><p>Data related to smoking or alcohol history in ADPKD trials are too limited to determine possible interactions of smoking or alcohol with efficacy and safety of ADPKD treatment with tolvaptan.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no or limited amount of data from the use of tolvaptan in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Tolvaptan is contraindicated during pregnancy (see section 4.3). Women of childbearing potential have to use effective contraception during tolvaptan treatment.</p><p><u>Breast-feeding</u></p><p>It is unknown whether tolvaptan is excreted in human milk.</p><p>Available pharmacodynamic/toxicological data in animals have shown excretion of tolvaptan in breast milk (for details see 5.3).</p><p>The potential risk for humans is unknown.</p><p>Tolvaptan is contraindicated during breast-feeding (see section 4.3).</p><p><u>Fertility</u></p><p>Studies in animals showed effects on fertility (see section 5.3). The potential risk for humans is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vaprena has no or negligible influence on the ability to drive or use machines. However, when driving or using machines it should be taken into account that occasionally dizziness, asthenia or syncope may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The pharmacodynamically predictable and most commonly reported adverse reactions are thirst, polyuria, nocturia, and pollakiuria occurring in approximately 55 %, 38 %, 29 % and 23 % of patients, respectively. Furthermore, tolvaptan has been associated with idiosyncratic elevations of blood alanine aminotransferase (ALT; 4.4 %) and aspartate aminotransferases (AST; 3.1 %) with infrequent cases of concomitant elevations in bilirubin-total (BT; 0.2 %).</p><p>The adverse reaction profile of tolvaptan in SIADH is based on a clinical trials database of 3,294 tolvaptan-treated patients and is consistent with the pharmacology of the active substance. The pharmaco-dynamically predictable and most commonly reported adverse reactions are thirst, dry mouth and pollakiuria occurring in approximately 18 %, 9 % and 6 % of patients.</p><p><u>Tabulated list of adverse reactions</u></p><p>The frequencies of the adverse reactions from clinical trials correspond with very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>The frequency of adverse reactions reported during post-marketing use cannot be determined as they are derived from spontaneous reports. Consequently, the frequency of these adverse reactions is qualified as &quot;not known&quot;.</p><table border="1" cellspacing="0" cellpadding="0" style="width:653px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anaphylactic shock,</p><p>Generalized rash</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Polydipsia</p></td><td style="vertical-align:top"><p>Dehydration,</p><p>Hyperkalemia,</p><p>Hyperglycemia,</p><p>Hypoglycemia<sup>1</sup>,</p><p>Hypernatremia<sup>1</sup>,</p><p>Hyperuricemia<sup>1</sup>,</p><p>Decreased appetite</p><p>Gout</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Psychiatric</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache,</p><p>Dizziness</p></td><td style="vertical-align:top"><p>Dysgeusia,</p><p>Syncope,</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Cardiac</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory,</p><p>thoracic and</p><p>mediastinal</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Orthostatic hypotension</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea,</p><p>Diarrhoea,</p><p>Dry mouth</p></td><td style="vertical-align:top"><p>Abdominal pain,</p><p>Abdominal distension,</p><p>Constipation,</p><p>Dyspepsia,</p><p>Gastroesophageal reflux disease,</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Ecchymosis,</p><p>Pruritus,</p><p>Dry skin,</p><p>Rash,</p><p>Urticaria</p></td><td style="vertical-align:top"><p>Pruritic rash<sup>1</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal</p><p>and connective</p><p>tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arthralgia,</p><p>Muscle spasms,</p><p>Myalgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Nocturia,</p><p>Pollakiuria,</p><p>Polyuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Renal impairment</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Fatigue, Thirst</p></td><td style="vertical-align:top"><p>Asthenia,</p><p>Pyrexia,</p><p>Malaise<sup>1</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Abnormal hepatic function</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Acute hepatic</p><p>failure<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Blood urine present<sup>1</sup>,</p><p>Alanine aminotransferase increased (see section 4.4)<sup>1</sup>, Aspartate aminotransferase increased (see section 4.4)<sup>1</sup>, Blood creatinine increased,</p><p>Weight decreased,</p><p>Weight increased</p></td><td style="vertical-align:top"><p>Bilirubin increased (see section 4.4)<sup>1</sup></p></td><td style="vertical-align:top"><p>Elevated transaminases<sup>2</sup></p></td></tr><tr><td style="vertical-align:top"><p>Surgical and medical procedures</p></td><td style="vertical-align:top"><p>Rapid correction of hyponatremia, sometimes leading to neurological symptoms</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p><sup>1</sup>&nbsp;observed in clinical trials investigating other indications</p><p><sup>2</sup>&nbsp;from post-authorization safety study in hyponatremia secondary to SIADH</p><p><sup>3</sup>&nbsp;observed in post-marketing with tolvaptan in ADPKD. Liver transplantation was necessary.</p><p><u>Description of selected adverse reactions</u></p><p><em>Laboratory results</em></p><p>Elevation (&gt; 3 &times; upper limit of normal [ULN]) of ALT was observed in 4.4 % (42/958) of patients on tolvaptan and 1.0 % (5/484) of patients on placebo, while elevation (&gt; 3 &times; ULN) of AST was observed in 3.1 % (30/958) of patients on tolvaptan and 0.8 % (4/484) patients on placebo in a double-blind, placebo-controlled trial in patients with ADPKD. Two (2/957, 0.2 %) of these tolvaptan treated-patients, as well as a third patient from an extension open label trial, exhibited increases in hepatic enzymes (&gt; 3 &times; ULN) with concomitant elevations in BT (&gt; 2 &times; ULN).</p><p><em>Rapid correction of hyponatremia</em></p><p>In a post-authorization safety study of tolvaptan in hyponatremia secondary to SIADH, including a high proportion of patients with tumours (especially Small Cell Lung Cancer), patients with low baseline serum sodium as well as patients with concomitant use of diuretics and/or sodium chloride solution the incidence of rapid correction of hyponatremia was found to be higher than in clinical trials.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p><u>Please report adverse drug events to: </u></p><p><strong>For Saudi Arabia:</strong></p><p>The National Pharmacovigilance Centre (NPC):</p><p>Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p><strong>For UAE</strong></p><p>Pharmacovigilance &amp; Medical Device section</p><p>P.O.Box: 1853 </p><p>Tel: 80011111</p><p>Email: pv@moh.gov.ae</p><p>Drug Department Ministry of Health &amp; Prevention, Dubai, UAE.</p><p><strong>For Oman</strong></p><p>Department of Pharmacovigilance &amp; Drug Information</p><p>Directorate General of Pharmaceutical Affairs &amp; Drug Control</p><p>Ministry of Health, Sultanate of Oman</p><p>Phone Nos. 22357687 / 22357686</p><p>Fax: 22358489</p><p>Email: dg-padc@moh.gov.om</p><p>Website: www.moh.gov.om</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single doses up to 480 mg and multiple doses up to 300 mg per day for 5 days have been well tolerated in clinical trials in healthy volunteers. There is no specific antidote for tolvaptan intoxication. The signs and symptoms of an acute overdose can be anticipated to be those of excessive pharmacologic effect: a rise in serum sodium concentration, polyuria, thirst and dehydration/hypovolemia (profuse and prolonged aquaresis).</p><p>No mortality was observed in rats or dogs following single oral doses of 2,000 mg/kg (maximum feasible dose). A single oral dose of 2,000 mg/kg was lethal in mice and symptoms of toxicity in affected mice included decreased locomotor activity, staggering gait, tremor and hypothermia.</p><p>In patients with suspected tolvaptan overdose, assessment of vital signs, electrolyte concentrations, ECG and fluid status is recommended. Appropriate replacement of water and/or electrolytes must continue until aquaresis abates. Dialysis may not be effective in removing tolvaptan because of its high binding affinity for human plasma protein (&gt; 98 %).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Diuretics, vasopressin antagonists, ATC code: C03XA01</p><p><u>Mechanism of action</u></p><p>Tolvaptan is a selective vasopressin V2-receptor antagonist that specifically blocks the binding of arginine vasopressin (AVP) at the V2-receptor of the distal portions of the nephron. Tolvaptan affinity for the human V2-receptor is 1.8 times that of native AVP.</p><p><u>Pharmacodynamic effects</u></p><p>The pharmacodynamic effects of tolvaptan have been determined in healthy subjects and subjects with ADPKD across CKD stages 1 to 4. Effects on free water clearance and urine volume are evident across all CKD stages with smaller absolute effects observed at later stages, consistent with the declining number of fully functioning nephrons. Acute reductions in mean total kidney volume were also observed following 3 weeks of therapy in all CKD stages, ranging from &minus;4.6 % for CKD stage 1 to &minus;1.9 % for CKD stage 4.</p><p>In healthy adult subjects, oral administration of 7.5 to 120 mg doses of tolvaptan produced an increase in urine excretion rate within 2 hours of dosing. Following single oral doses of 7.5 to 60 mg, 24-hour urine volume increased dose dependently with daily volumes ranging from 3 to 9 liters. For all doses, urine excretion rates returned to baseline levels after 24 hours. For single doses 60 mg to 480 mg, a mean of about 7 liters was excreted during 0 to 12 hours, independent of dose. Markedly higher doses of tolvaptan produce more sustained responses without affecting the magnitude of excretion, as active concentrations of tolvaptan are present for longer periods of time.</p><p><u>Clinical efficacy and safety</u></p><p><em>Hyponatremia</em></p><p>In 2 pivotal, double-blind, placebo-controlled, clinical trials, a total of 424 patients with euvolemic or hypervolemic hyponatremia (serum sodium &lt; 135 mEq/L) due to a variety of underlying causes (heart failure [HF], liver cirrhosis, SIADH and others) were treated for 30 days with tolvaptan (n = 216) or placebo (n = 208) at an initial dose of 15 mg/day. The dose could be increased to 30 and 60 mg/day depending on response using a 3-day titration scheme. The mean serum sodium concentration at trial entry was 129 mEq/L (range 114-136).</p><p>The primary endpoint for these trials was the average daily AUC for change in serum sodium from baseline to Day 4 and baseline to Day 30. Tolvaptan was superior to placebo (p &lt; 0.0001) for both periods in both studies. This effect was seen in all patients, the severe (serum sodium: &lt; 130 mEq/L) and mild (serum sodium: 130 -&lt; 135 mEq/L) subsets and for all disease aetiology subsets (e.g. HF, cirrhosis, SIADH/other). At 7 days after discontinuing treatment, sodium values decreased to levels of placebo treated patients.</p><p>Following 3 days of treatment, the pooled analysis of the two trials revealed five-fold more tolvaptan than placebo patients achieved normalization of serum sodium concentrations (49 %&nbsp;<em>vs.</em>&nbsp;11 %). This effect continued as on Day 30, when more tolvaptan than placebo patients still had normal concentrations (60 %&nbsp;<em>vs.</em>&nbsp;27 %). These responses were seen in patients independent of the underlying disease. The results of self-assessed health status using the SF-12 Health Survey for the mental scores showed statistically significant and clinically relevant improvements for tolvaptan treatment compared to placebo.</p><p>Data on the long-term safety and efficacy of tolvaptan were assessed for up to 106 weeks in a clinical trial in patients (any etiology) who had previously completed one of the pivotal hyponatremia trials. A total of 111 patients started tolvaptan treatment in an open-label, extension trial, regardless of their previous randomization. Improvements in serum sodium levels were observed as early as the first day after dosing and continued for on-treatment assessments up to Week 106. When treatment was discontinued, serum sodium concentrations decreased to approximately baseline values, despite the reinstatement of standard care therapy.</p><p>In a pilot, randomized (1:1:1), double-blind trial in 30 patients with hyponatremia secondary to SIADH, the pharmacodynamics of tolvaptan following single doses of 3.75, 7.5 and 15 mg were assessed. Results were highly variable with large overlap between dose groups; changes were not significantly correlated with tolvaptan exposure. Mean maximal changes in serum sodium were highest following the 15 mg dose (7.9 mmol/L) but median maximal changes were highest for the 7.5 mg dose (6.0 mmol/L). Individual maximal increases in serum sodium were negatively correlated with fluid balance; mean change in fluid balance showed a dose dependent decrease. Mean change from baseline in cumulative urine volume and urine excretion rates was 2-fold higher for the 15 mg dose compared to the 7.5 and 3.75 mg doses, which showed similar responses.</p><p><em>Heart failure</em></p><p>EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan) was a long-term outcome, double-blind, controlled clinical trial in patients hospitalized with worsening HF and signs and symptoms of volume overload. In the long-term outcome trial, a total of 2,072 patients received 30 mg tolvaptan with standard of care (SC) and 2,061 received placebo with SC. The primary objective of the study was to compare the effects of tolvaptan + SC with placebo + SC on the time to all-cause mortality and on the time to first occurrence of cardiovascular (CV) mortality or hospitalization for HF. Tolvaptan treatment had no statistically significant favorable or unfavorable effects on overall survival or the combined endpoint of CV mortality or HF hospitalization, and did not provide convincing evidence for clinically relevant benefit.</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with Name in one or more subsets of the pediatric population in treatment of dilutional hyponatremia (see section 4.2 for information on pediatric use).</p><p><em>Polycystic kidney disease</em><em> </em></p><p>The primary focus of the clinical program for development of tolvaptan tablets for the treatment of ADPKD is a single pivotal, multi-national, phase 3, randomised, placebo-controlled trial in which the long-term safety and efficacy of oral split dose tolvaptan regimens (titrated between 60 mg/day and 120 mg/day) were compared with placebo in 1,445 adult subjects with ADPKD.</p><p>In total, 14 clinical trials involving tolvaptan have been completed worldwide in support of the ADPKD indication, including 8 trials in the US, 1 in the Netherlands, 3 in Japan, 1 in Korea, and the multinational phase 3 pivotal trial.</p><p>The phase 3 pivotal trial (TEMPO 3:4, 156-04-251) included subjects from 129 centres in the Americas, Japan, Europe and other countries. The primary objective of this trial was to evaluate the long-term efficacy of tolvaptan in ADPKD through rate of total kidney volume (TKV) change (normalised as percentage; %) for tolvaptan-treated compared with placebo-treated subjects. In this trial a total of 1,445 adult patients (age 18 years to 50 years) with evidence of rapidly-progressing, early ADPKD (meeting modified Ravine criteria, TKV &ge; 750 mL, estimated creatinine clearance &ge; 60 mL/min) were randomised 2:1 to treatment with tolvaptan or placebo. Patients were treated for up to 3 years.</p><p>Tolvaptan (n = 961) and placebo (n = 484) groups were well matched in terms of gender with an average age of 39 years. The inclusion criteria identified patients who at baseline had evidence of early disease progression. At baseline, patients had average estimated glomerular filtration rate (eGFR) of 82 mL/min/1.73 m2 (Chronic Kidney Disease-Epidemiology Collaboration; CKD-EPI) with 79 % having hypertension and a mean TKV of 1,692 mL (height adjusted 972 mL/m). Approximately 35 % of subjects were CKD stage 1, 48 % CKD stage 2, and 17 % CKD stage 3 (eGFRCKD-EPI). While these criteria were useful in enriching the study population with patients who were rapidly progressing, subgroup analyses based on stratification criteria (age, TKV, GFR, Albuminuria, Hypertension) indicated the presence of such risk factors at younger ages predicts more rapid disease progression.</p><p>The results of the primary endpoint, the rate of change in TKV for subjects randomized to tolvaptan (normalized as percentage, %) to the rate of change for subjects on placebo, were highly statistically significant. The rate of TKV increase over 3 years was significantly less for tolvaptan-treated subjects than for subjects receiving placebo: 2.80 % per year versus 5.51 % per year, respectively (ratio of</p><p>geometric mean 0.974; 95 % CI 0.969 to 0.980; p &lt; 0.0001).</p><p>Pre-specified secondary endpoints were tested sequentially. The key secondary composite endpoint (ADPKD progression) was time to multiple clinical progression events of:</p><p>1) Worsening kidney function (defined as a persistent [reproduced over at least 2 weeks] 25 % reduction in reciprocal serum creatinine during treatment [from end of titration to last on medicinal product visit])</p><p>2) Medically significant kidney pain (defined as requiring prescribed leave, last-resort analgesics, narcotic and anti-nociceptive, radiologic or surgical interventions)</p><p>3) Worsening hypertension</p><p>4) Worsening albuminuria</p><p>The relative rate of ADPKD-related events was decreased by 13.5 % in tolvaptan-treated patients, (hazard ratio, 0.87; 95 % CI, 0.78 to 0.97; p = 0.0095).</p><p>The result of the key secondary composite endpoint is primarily attributed to effects on worsening kidney function and medically significant kidney pain. The renal function events were 61.4 % less likely for tolvaptan compared with placebo (hazard ratio, 0.39; 95 % CI, 0.26 to 0.57; nominal p &lt; 0.0001), while renal pain events were 35.8 % less likely in tolvaptan-treated patients (hazard ratio, 0.64; 95 % CI, 0.47 to 0.89; nominal p = 0.007). In contrast, there was no effect of tolvaptan on either progression of hypertension or albuminuria.</p><p>TEMPO 4:4 is an open-label extension study that included 871 subjects that completed TEMPO 3:4 from 106 centres across 13 countries. This trial evaluated the effects of tolvaptan on safety, TKV and eGFR in subjects receiving active treatment for 5 years (early-treated), compared with subjects treated with placebo for 3 years, then switched to active treatment for 2 years (delayed-treated).</p><p>The primary end point for TKV did not distinguish a difference in change (&minus;1.7 %) over the 5-year treatment between early- and delayed-treated subjects at the pre-specified threshold of statistical significance (p = 0.3580). Both groups&rsquo; TKV growth trajectory was slowed, relative to placebo in the first 3 years, suggesting both early- and delayed- tolvaptan treated subjects benefitted to a similar degree.</p><p>A secondary endpoint testing the persistence of positive effects on renal function indicated that the preservation of eGFR observed by the end of the TEMPO 3:4 pivotal trial (3.01 to 3.34 mL/min/1.73 m<sup>2</sup> at follow-up visits 1 and 2) could be preserved during open-label treatment. This difference was maintained in the pre-specified mixed effect model repeat measurement (MMRM) analysis (3.15 mL/min/1.73 m2, 95 %CI 1.462 to 4.836, p = 0.0003) and with sensitivity analyses where baseline eGFR data were carried forward (2.64 mL/min/1.73 m2, 95 % CI 0.672 to 4.603, p = 0.0086). These data suggest that tolvaptan can slow the rate of renal function decline, and that these benefits persist over the duration of therapy.</p><p>Longer term data are not currently available to show whether long-term therapy with tolvaptan continues to slow the rate of renal function decline and affect clinical outcomes of ADPKD, including delay in the onset of end-stage renal disease.</p><p>Genotyping for <em>PKD1 </em>and <em>PKD2 </em>genes was conducted in a majority of patients entering the open-label extension study (TEMPO 4:4) but the results are not yet known.</p><p>Following an additional 2 years of tolvaptan treatment, resulting in a total of 5 years on tolvaptan therapy no new safety signals were identified.</p><p>The phase 3, multi-center, international, randomized-withdrawal, placebo-controlled, double-blind trial 156-13-210 compared the efficacy and safety of tolvaptan (45 mg/day to 120 mg/day) to placebo in patients able to tolerate tolvaptan during a five-week titration and run-in period on tolvaptan. The trial utilized a randomized withdrawal design, to enrich for patients that were able to tolerate tolvaptan for a</p><p>5-week, single-blind pre-randomization period consisting of a 2-week titration period and 3-week run-in period. The design was used to minimise the impact of early discontinuation and missing data on trial endpoints.</p><p>A total of 1,370 patients (age 18 years to 65 years) with CKD with an eGFR between 25 and 65 mL/min/1.73 m2 if younger than age 56 years; or eGFR between 25 and 44 mL/min/1.73 m2, plus eGFR decline &gt;2.0 mL/min/1.73 m2/year if between age 56 years to 65 years were randomized to either tolvaptan (n = 683) or placebo (n = 687) and were treated for a period of 12 months.</p><p>For subjects randomized, the baseline, average eGFR was 41 mL/min/1.73 m2 (CKD-EPI) and historical TKV, available in 318 (23 %) of subjects, averaged 2,026 mL. Approximately 5 %, 75 % and 20 % had an eGFR 60 mL/min/1.73 m2 or greater (CKD stage 2), or less than 60 and greater than 30 mL/min/1.73 m2 (CKD stage 3) or less than 30 but greater than 15 mL/min/1.73 m2 (CKD stage 4), respectively. The CKD stage 3 can be subdivided further to stage 3a 30 %, (eGFR 45 mL/min/1.73 m2</p><p>to less than 60 mL/min/1.73 m2) and stage 3b 45 %, (eGFR between 30 and 45 mL/min/1.73 m2).</p><p>The primary endpoint of the trial was the change in eGFR from pre-treatment baseline levels to posttreatment assessment. In patients treated with tolvaptan the reduction in eGFR was significantly less than in patients treated with placebo (p &lt; 0.0001). The treatment difference in eGFR change observed in this trial is 1.27 mL/min/1.73 m2, representing a 35 % reduction in the LS means of change in eGFR of &minus;2.34 mL/min/1.73 m2 in tolvaptan group relative to a &minus;3.61 mL/min/1.73 m2 in placebo group observed over the course of one year. The key secondary endpoint was a comparison of the efficacy of tolvaptan treatment <em>versus </em>placebo in reducing the decline of annualized eGFR slope across all measured time points in the trial. These data also showed significant benefit from tolvaptan <em>versus</em> placebo (p &lt; 0.0001).</p><p>Subgroup analysis of the primary and secondary endpoints by CKD stage found similar, consistent treatment effects relative to placebo for subjects in stages 2, 3a, 3b and early stage 4 (eGFR 25 to 29 mL/min/1.73 m2) at baseline.</p><p>A pre-specified subgroup analysis suggested that tolvaptan had less of an effect in patients older than 55 years of age, a small subgroup with a notably slower rate of eGFR decline.</p><p><em>Paediatric population</em></p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with tolvaptan in one or more subsets of the paediatric population in polycystic kidney disease (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>After oral administration, tolvaptan is rapidly absorbed with peak plasma concentrations occurring about 2 hours after dosing. The absolute bioavailability of tolvaptan is about 56 %. Co-administration of tolvaptan with a high-fat meal increased peak concentrations of tolvaptan up to 2-fold but left AUC unchanged. Even though the clinical relevance of this finding is not known, the morning dose should be taken under fasted conditions to minimize the unnecessary risk of increasing the maximal exposure (see section 4.2).<u> </u></p><p><u>Distribution</u></p><p>Following single oral doses of &ge; 300 mg, peak plasma concentrations appear to plateau, possibly due to saturation of absorption. Tolvaptan binds reversibly (98 %) to plasma proteins.</p><p><u>Biotransformation</u></p><p>Tolvaptan is extensively metabolized in the liver almost exclusively by CYP3A. Tolvaptan is a weak CYP3A4 substrate and does not appear to have any inhibitory activity. <em>In vitro </em>studies indicated that tolvaptan has no inhibitory activity for CYP3A. Fourteen metabolites have been identified in plasma, urine and faeces; all but one were also metabolised by CYP3A. Only the oxobutyric acid metabolite is present at greater than 10 % of total plasma radioactivity; all others are present at lower concentrations than tolvaptan. Tolvaptan metabolites have little to no contribution to the pharmacological effect of tolvaptan; all metabolites have no or weak antagonist activity for human V2 receptors when compared with tolvaptan. The terminal elimination half-life is about 8 hours and steady-state concentrations of tolvaptan are obtained after the first dose.<u> </u></p><p><u>Elimination</u></p><p>Less than 1 % of intact active substance is excreted unchanged in the urine. The terminal elimination half-life is about 8 hours and steady-state concentrations of tolvaptan are obtained after the first dose.</p><p>Radio labelled tolvaptan experiments showed that 40 % of the radioactivity was recovered in the urine and 59 % was recovered in the faeces where unchanged tolvaptan accounted for 32 % of radioactivity. Tolvaptan is only a minor component in plasma (3 %).</p><p><u>Linearity</u></p><p>Tolvaptan has linear pharmacokinetics for doses of 7.5 to 60 mg.</p><p>Following single oral doses, Cmax values show less than dose proportional increases from 30 mg to 240 mg and then a plateau at doses from 240 mg to 480 mg. AUC increases linearly.</p><p>Following multiple once daily dosing of 300 mg, tolvaptan exposure was only increased 6.4-fold when compared to a 30 mg dose. For split-dose regimens of 30 mg/day, 60 mg/day and 120 mg/day in ADPKD patients, tolvaptan exposure (AUC) increases linearly.</p><p><u>Pharmacokinetics in special patient groups</u></p><p><em>Age</em></p><p>Clearance of tolvaptan is not significantly affected by age.</p><p><em>Hepatic impairment</em></p><p>The effect of mildly or moderately impaired hepatic function (Child-Pugh classes A and B) on the pharmacokinetics of tolvaptan was investigated in 87 patients with liver disease of various origins. No clinically significant changes have been seen in clearance for doses ranging from 5 to 60 mg. Very limited information is available in patients with severe hepatic impairment (Child-Pugh class C).</p><p>In a population pharmacokinetic analysis in patients with hepatic edema, AUC of tolvaptan in severely (Child-Pugh class C) and mildly or moderately (Child-Pugh classes A and B) hepatic impaired patients were 3.1 and 2.3 times higher than that in healthy subjects.</p><p><em>Renal impairment</em></p><p>In an analysis on population pharmacokinetics for patients with heart failure, tolvaptan concentrations of patients with mildly (creatinine clearance [C<sub>cr</sub>] 50 to 80 mL/min) or moderately (C<sub>cr</sub>&nbsp;20 to 50 mL/min) impaired renal function were not significantly different to tolvaptan concentrations in patients with normal renal function (C<sub>cr</sub>&nbsp;80 to 150 mL/min). The efficacy and safety of tolvaptan in those with a creatinine clearance &lt; 10 mL/min has not been evaluated and is therefore unknown.</p><p>In a population pharmacokinetic analysis for patients with ADPKD, tolvaptan concentrations were increased, compared to healthy subjects, as renal function decreased below eGFR of 60 mL/min/1.73 m<sup>2</sup>. An eGFR <sub>CKD-EPI</sub> decrease from 72.2 to 9.79 (mL/min/1.73 m2) was associated with a 32 % reduction in total body clearance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity or carcinogenic potential.</p><p>Teratogenicity was noted in rabbits given 1,000 mg/kg/day. No teratogenic effects were seen in rabbits at 300 mg/kg/day.</p><p>In a peri-and post-natal study in rats, delayed ossification and reduced pup bodyweight were seen at the high dose of 1,000 mg/kg/day.</p><p>Two fertility studies in rats showed effects on the parental generation (decreased food consumption and body weight gain, salivation), but tolvaptan did not affect reproductive performance in males and there were no effects on the foetuses. In females, abnormal oestrus cycles were seen in both studies.</p><p>The no observed adverse effects level (NOAEL) for effects on reproduction in females (100 mg/kg/day) was about 8-times the total daily dose of 60 mg/day on a mg/m<sup>2</sup>&nbsp;basis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Crospovidone,</p><p>Povidone,</p><p>Butylated Hydroxytoluene,</p><p>Microcrystalline Cellulose,</p><p>Lactose Monohydrate,</p><p>Pregelatinized Starch,</p><p>Croscarmellose Sodium,</p><p>Colloidal Silicon Dioxide,</p><p>Magnesium Stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&ordm; C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vaprena 15 mg and Vaprena 30 mg tablets:</p><p>PVC/PVDC/Al/paper blister; 10 tablets per blister strip for both of 15 mg &amp; 30 mg.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufacturer: Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Marketing Authorization Holder:
SPIMACO
Al-Qassim Pharmaceutical Plant
Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2022.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>